P34 A paediatric pseudo-asthma cade study

    loading  Checking for direct PDF access through Ovid


Background and aims

The aim of this study was to evaluate and monitor the natural history of the disease and to establish a reliable tool of proper medication and asthma vulnerability assessment for a child patient with cellular immunity deficiency and congenital aortic arch anomaly in ultrasound monitoring



a boy whose respiratory condition was evaluated during almost 14 years period. His critical point started from age of six months, when exhibited recurrent wheezing. At age of two years was diagnosed with asthma and at age of four years exhibited a positive reaction on a TB (tuberculosis) skin test, while clinical features and medical analysis did not confirm severe cardiac and pulmonary disease. During his childhood he presented several respiratory infections and 2–3 recurrent asthma attacks per year. At 12 years age he exhibited an exacerbation of hypertension blood pressure and computed tomography showed a cardiac malformation, button aorta has a right footprint on the trachea, the trail descending aorta being partially right side. Parent of investigated subject agreed and signed an informed consent. Several clinical and laboratory evaluations each three month for each year with adequate protocols have been performed.Regularly control of immunoglobulin levels IgE, IgA, IgG and IgM was done. A specific anti-asthma medication during early years till now (LT inhibitors, corticosteroids CIS agonists),and immunomodulatory treatment (Luivac, Thym-Uvocal),vitamin therapy (Ca, D3, Magne B6) and CoQ10 have been administrated.


In this research setting was necessary to develop outcomes measure that are clinically significant, and sufficiently sensitive and able to focus on individual health improvement which can guide research to proper therapeutic methodologies. The findings are relevant clinically and should have a positive high impact on children with congenital cardiac anomalies pathophysiology improvement.


Current adopted therapies are able to control symptoms and possible modulate immunological dysregulation that characterises respiratory disorders. This information brings us closer to the point of managing children with controllable asthma and understanding reasons, therapy improvement, and new insights into treatment in order to better methods to intervene early in the course of the disease and induce clinical remission as quickly as possible for patient.

Related Topics

    loading  Loading Related Articles